Multiple small-molecule uremic toxins and intestinal metabolites

Multiple small-molecule uremic toxins and intestinal metabolites are a heterogeneous group of compounds that accumulate in patients with chronic kidney disease (CKD) due to decreased renal clearance (Duranton et al., 2012, Journal of the American Society of Nephrology). These molecules are primarily generated through the metabolic activity of gut microbiota, which break down dietary precursors like tryptophan and tyrosine into compounds such as indoxyl sulfate and p-cresyl sulfate (Niwa, 2011, Journal of Renal Nutrition). Once absorbed into the systemic circulation, these toxins exert deleterious effects by promoting oxidative stress, inflammation, and fibrosis in various organs, particularly the heart and kidneys (Vanholder et al., 2014, Nature Reviews Nephrology). High levels of these metabolites are strongly associated with the progression of CKD and an increased risk of cardiovascular complications (Tang et al., 2013, New England Journal of Medicine). Unlike traditional drug targets such as receptors or enzymes, these toxins are pathological solutes that therapies aim to sequester, degrade, or prevent from forming. Pharmacological interventions include oral adsorbents like AST-120, which bind toxin precursors in the gut to prevent their absorption (Schulman et al., 2015, American Journal of Kidney Diseases). Other emerging approaches involve the use of prebiotics, probiotics, or engineered live biotherapeutics to modulate the gut microbiome and reduce the biosynthetic output of these harmful metabolites (Ramezani et al., 2014, Journal of the American Society of Nephrology). Monitoring the levels of these toxins serves as a critical biomarker for assessing renal function and the efficacy of uremia-targeted therapies.

Other names

Uremic toxinsUremic retention solutesGut-derived uremic toxinsMicrobiota-derived metabolitesProtein-bound uremic toxins

Gastrointestinal adsorption of biosynthetic precursors to prevent systemic absorption and reduction of metabolite production through modulation of the gut microbiome.